

Prashant Ramesh Tembhare

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6716594/publications.pdf>

Version: 2024-02-01

66
papers

2,163
citations

623734

14
h-index

265206

42
g-index

67
all docs

67
docs citations

67
times ranked

1411
citing authors

#	ARTICLE	IF	CITATIONS
1	Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease. <i>British Journal of Haematology</i> , 2022, 196, 374-379.	2.5	3
2	Comprehensive immune cell profiling depicts an early immune response associated with severe coronavirus disease 2019 in cancer patients. <i>Immunology and Cell Biology</i> , 2022, 100, 61-73.	2.3	6
3	Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis. <i>Cytometry Part B - Clinical Cytometry</i> , 2022, 102, 88-106.	1.5	10
4	Genomic Analysis of AZD1222 (ChAdOx1) Vaccine Breakthrough Infections in the City of Mumbai. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-9.	1.7	0
5	Detecting hypodiploidy with endoreduplication and masked hypodiploidy in B-cell acute lymphoblastic leukemia using multicolor flow cytometry. <i>Cytometry Part B - Clinical Cytometry</i> , 2022, , .	1.5	3
6	Critical Role of Flow Cytometric Immunophenotyping in the Diagnosis, Subtyping, and Staging of T-Cell/NK-Cell Non-Hodgkin's Lymphoma in Real-World Practice: A Study of 232 Cases From a Tertiary Cancer Center in India. <i>Frontiers in Oncology</i> , 2022, 12, 779230.	2.8	5
7	Copy number gain of <i>JAK2</i> on marker chromosome in a case of relapsed pediatric B-ALL. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29658.	1.5	2
8	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. <i>Leukemia</i> , 2022, 36, 1703-1719.	7.2	1,211
9	Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 434-445.	1.5	9
10	Eleven-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 421-433.	1.5	14
11	Cytogenetic profile and outcome of a pediatric acute promyelocytic leukemia patient presenting with isolated isochromosome 17q in absence of RARA rearrangement. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 88, 102443.	1.4	0
12	Mast cell differentiation of leukemic blasts in diverse myeloid neoplasms: A potential premyelomastocytic leukemia condition. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 331-344.	1.5	2
13	Sudden blast phase in pediatric chronic myeloid leukemia—chronic phase with abnormal lymphoid blasts detected by flow cytometry at diagnosis: Can it be considered a warning sign?. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 345-351.	1.5	6
14	Utility of <i>CD36</i> as a novel addition to the immunophenotypic signature of <i>RAM</i> phenotype acute myeloid leukemia and study of its clinicopathological characteristics. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 206-217.	1.5	7
15	Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol. <i>Blood Advances</i> , 2021, 5, 1178-1193.	5.2	19
16	Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML). <i>Leukemia</i> , 2021, 35, 1392-1404.	7.2	51
17	Importance of conventional cytogenetics in the identification of <i>ins(19;X)(q13.1;p11.2q28)</i> and <i>t(1;11)(q10;p10)</i> , both, novel cytogenetic abnormalities in a pediatric AML case. <i>Cancer Genetics</i> , 2021, 256-257, 17-20.	0.4	0
18	Mutational landscape of Juvenile Myelomonocytic Leukemia (JMML)—A real-world context. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1531-1538.	1.3	4

#	ARTICLE	IF	CITATIONS
19	Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 3436-3444.	5.2	6
20	Expression of CD304/neuropilin-1 in adult B-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 990-999.	1.3	4
21	A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2 ⁶ and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 57-67.	1.5	52
22	Investigating the clinical, hematological and cytogenetic profile of endoreduplicated hypodiploids in BCP-ALL. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 85, 102465.	1.4	2
23	NARASIMHA: Novel Assay based on Targeted RNA Sequencing to Identify ChiMeric Gene Fusions in Hematological Malignancies. <i>Blood Cancer Journal</i> , 2020, 10, 50.	6.2	9
24	Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center. <i>JCO Global Oncology</i> , 2020, 6, 1684-1695.	1.8	11
25	Machine learning derived genomics driven prognostication for acute myeloid leukemia with RUNX1-RUNX1T1. <i>Leukemia and Lymphoma</i> , 2020, 61, 3154-3160.	1.3	8
26	CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 328-335.	1.5	13
27	Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy. , 2020, 8, e000630.		30
28	The Th9 Axis Reduces the Oxidative Stress and Promotes the Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma Patients. <i>Molecular Cancer Research</i> , 2020, 18, 657-668.	3.4	17
29	Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients. <i>Frontiers in Oncology</i> , 2020, 10, 577.	2.8	13
30	A novel machine-learning-derived genetic score correlates with measurable residual disease and is highly predictive of outcome in acute myeloid leukemia with mutated NPM1. <i>Blood Cancer Journal</i> , 2019, 9, 79.	6.2	13
31	Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context. <i>Frontiers in Oncology</i> , 2019, 9, 450.	2.8	14
32	Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international interlaboratory study: Is it ready for primetime use?. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 201-208.	1.5	15
33	Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 509-519.	1.5	14
34	Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; OOB: 000-000. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 100-111.	1.5	47
35	Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 178-186.	1.3	2
36	Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia. <i>Oncotarget</i> , 2018, 9, 36613-36624.	1.8	26

#	ARTICLE	IF	CITATIONS
37	Long term clinical outcomes of adult hematolymphoid malignancies treated at Tata Memorial Hospital: An institutional audit. Indian Journal of Cancer, 2018, 55, 9.	0.2	9
38	Applicability of 2008 World Health Organization classification system of hematolymphoid neoplasms: Learning experiences. Indian Journal of Pathology and Microbiology, 2018, 61, 58.	0.2	0
39	CD19 negative precursor B acute lymphoblastic leukemia (B-ALL) – Immunophenotypic challenges in diagnosis and monitoring: A study of three cases. Cytometry Part B - Clinical Cytometry, 2017, 92, 315-318.	1.5	13
40	Method for DNA Ploidy Analysis Along with Immunophenotyping for Rare Populations in a Sample using FxCycle Violet. Current Protocols in Cytometry, 2017, 80, 6.38.1-6.38.15.	3.7	9
41	MOLECULAR HETEROGENEITY IN ACUTE PROMYELOCYTIC LEUKEMIA - A SINGLE CENTRE EXPERIENCE FROM INDIA. Mediterranean Journal of Hematology and Infectious Diseases, 2017, 10, 2018002.	1.3	9
42	Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders. Indian Journal of Hematology and Blood Transfusion, 2017, 33, 303-315.	0.6	6
43	Clinicoepidemiological profiles, clinical practices, and the impact of holistic care interventions on outcomes of pediatric hematolymphoid malignancies - A 7-year audit of the pediatric hematolymphoid disease management group at Tata Memorial Hospital. Indian Journal of Cancer, 2017, 54, 609.	0.2	15
44	A rare extramedullary and extralymphoid presentation of mixed phenotypic blastic hematolymphoid neoplasm: A study of two cases. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 394.	0.2	5
45	Biclonal chronic lymphocytic leukemia: A study of two cases and review of literature. Indian Journal of Pathology and Microbiology, 2017, 60, 84-86.	0.2	0
46	A novel and easy FxCycle violet based flow cytometric method for simultaneous assessment of DNA ploidy and six color immunophenotyping. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2016, 89, 281-291.	1.5	23
47	Population pharmacokinetics of Reditux, a biosimilar Rituximab, in diffuse large B-cell lymphoma. Cancer Chemotherapy and Pharmacology, 2016, 78, 353-359.	2.3	31
48	'Childhood systemic mastocytosis associated with t (8; 21) (q22; q22) acute myeloid leukemia'. Indian Journal of Pathology and Microbiology, 2016, 59, 407.	0.2	2
49	Lymphoblastic leukemia with surface light chain restriction: A diagnostic dilemma. Indian Journal of Pathology and Microbiology, 2016, 59, 410.	0.2	1
50	Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leukemia Research, 2014, 38, 371-376.	0.8	76
51	A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica, 2014, 99, e81-e83.	3.5	112
52	Distinguishing hairy cell leukemia variant from hairy cell leukemia: Development and validation of diagnostic criteria. Leukemia Research, 2013, 37, 401-409.	0.8	100
53	Quantification of Expression of Antigens Targeted by Antibody-Based Therapy in Chronic Lymphocytic Leukemia. American Journal of Clinical Pathology, 2013, 140, 813-818.	0.7	17
54	Biologic variations of plasma cells in the bone marrow of smoldering multiple myeloma (SMM) and multiple myeloma (MM) patients: Multiple biopsies in the same patient.. Journal of Clinical Oncology, 2013, 31, e19506-e19506.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression. <i>Leukemia and Lymphoma</i> , 2012, 53, 721-724.	1.3	9
56	Flow Cytometric Immunophenotypic Assessment of T-Cell Clonality by V β 2 Repertoire Analysis in Fine-Needle Aspirates and Cerebrospinal Fluid. <i>American Journal of Clinical Pathology</i> , 2012, 137, 220-226.	0.7	25
57	Case study interpretation—Portland: Case 1. <i>Cytometry Part B - Clinical Cytometry</i> , 2012, 82B, 177-179.	1.5	5
58	Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, e18568-e18568.	1.6	4
59	A prospective clinical study evaluating current models for risk of progression from smoldering multiple myeloma (SMM) to multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8088-8088.	1.6	0
60	Hevylite [®] Assays Detect a Hidden Immunoparesis Associated with Adverse Biology in Myeloma Precursor Disease: A Prospective Clinical Study. <i>Blood</i> , 2011, 118, 5065-5065.	1.4	1
61	Immunophenotypic profile of plasma cell leukemia: A retrospective study in a reference cancer center in India and review of literature. <i>Indian Journal of Pathology and Microbiology</i> , 2011, 54, 294.	0.2	10
62	Immunophenotypic Profile in Acute Infectious Mononucleosis Mimicking Malignant Lymphoproliferative Disorder: A Case Report and Review of Literature. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2010, 26, 118-121.	0.6	3
63	Intracytoplasmic antigen study by flow cytometry in hematology neoplasm. <i>Indian Journal of Pathology and Microbiology</i> , 2009, 52, 135.	0.2	7
64	Exflagellated microgametes of <i>Plasmodium vivax</i> in human peripheral blood: A case report and review of the literature. <i>Indian Journal of Pathology and Microbiology</i> , 2009, 52, 252.	0.2	12
65	Hypergranular precursor B-cell acute lymphoblastic leukemia in a 16-year-old boy. <i>Indian Journal of Pathology and Microbiology</i> , 2009, 52, 421.	0.2	10
66	Hepatosplenic T-Cell Lymphoma Masquerading as T Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2008, 112, 5310-5310.	1.4	1